PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
Primary Purpose
Cancer, Lung Cancer Metastatic, Immunotherapy
Status
Unknown status
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
PDR001
Sponsored by
About this trial
This is an interventional treatment trial for Cancer
Eligibility Criteria
Inclusion Criteria:
- Subjects with histologically or cytologically confirmed, stage IV or recurrent NSCLC that carries a KRAS/NRAS mutation or no actionable mutation, which are identified by NGS.
- Squamous cell carcinoma and non-squamous cell carcinoma will be enrolled with 1:1 ratio for efficacy analysis according to histology
- Subjects who did not treated with prior anti-PD-1 antibody nor anti-PD-L1 antibodies
- ECOG performance status of 0 to 2
- Male or female; ≥ 18 years of age
- Patients those who showed disease progression after one or two prior platinum-containing regimen
- Patients who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for locally advanced disease are eligible, provided that progression has occurred ≥ 12 months from last therapy.
- Subjects with at least one measurable lesion (using RECIST 1.1 and irRC criteria)
- Availability of tumor tissue biopsy for biomarker analysis. Archival tissue can be used. Fine-needle aspirates will not be acceptable.
- Subjects who meet the following criteria:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥100 x 10^9/L
- Serum creatinine ≥ 1.5 x upper limit of normal (ULN)
- AST (SGOT) and ALT (SGPT) ≥ 3 x upper limit of normal (ULN) (If there is Liver Metastasis ≥ 5 x upper limit of normal (ULN))
- Total bilirubin≥1.5 x upper limit of normal (ULN)
- Life expectancy of ≥ 12 weeks on C1D1
- Provision of written informed consent prior to any study specific procedures
Exclusion Criteria:
- Patients who harboring EGFR mutation(s) and/or anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial.
- Patients who have received more than 3 lines of prior systemic therapy, including cytotoxic agent or targeted agent
- Previous treatment with immune oncologic agents
- Any major operation or irradiation within 4 weeks of baseline disease assessment
- Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms
- Subjects with history of leptomeningeal metastasis
- Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma or cervical cancer in situ. Any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC such as thyroid cancer.
- Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome (Corrected QT (QTcF) >470 ms using Fridericia's correction on the screening ECG), 2° or more AV Block and uncontrolled hypertension)
- Pregnant or lactating female
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
- History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
- Active, known or suspected autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn's disease (Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll).
- Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
- Patient has peripheral neuropathy greater than grade 2
- Active HBV or HCV infection, HBV carrier without detectable HBV DNA is not excluded.
- Known history of testing positive for Human Immunodeficiency Virus (HIV) infection
- Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.
- Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steoids are not prohibited.
- Use of any live vaccines against infectious disease within 4 weeks of initiation of study treatment.
- Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 150 days after the last dose of study treatment.
- Sexually active males unless they use a condom during treatment and for 150 days after stopping study treatment .
Sites / Locations
- Asan Medical CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PDR001
Arm Description
PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Outcomes
Primary Outcome Measures
Objective response rate
ORR is a proportion of patients with a best overall response defined as complete response or partial response by RECIST1.1
Secondary Outcome Measures
Duration of response
DOR is calculated as the time from the date of the first document of complete remission (CR) or partial remission (PR) to the first documented preogressive disease (PD) or death due to any cause for patients with PR or CR.
Progression-free survival
PFS is defined as time from the first dose of investigational products (IPs) to progression or death due to any cause.
OS is defined as time from the first dose of IPs to death due to any cause.
Overall survival
Disease control rate
DCR is calculated as the proportion of patients with best response of CR, PR and SD.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03693326
Brief Title
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
Official Title
An Open-label, Multicenter, Phase II Study of PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or Without Actionable Genetic Abnormalities, Detected Using NGS Platform
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Unknown status
Study Start Date
November 1, 2018 (Anticipated)
Primary Completion Date
June 30, 2020 (Anticipated)
Study Completion Date
June 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.
Detailed Description
This clinical study is targeted for the patients who harbor KRAS/NRAS mutation or no actionable genetic abnormalities detected using NGS platform and all patients will be treated with PDR001. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 21 days.
Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment.
The progression of the disease in most patients is defined radiographically and determined according to RECIST criteria ver. 1.1. If there are patients those who need to be provided investigational drug beyond predefined end of treatment, additional extended providing of PDR001 needs the mutual agreement of the investigators and Novartis followed by amendment of study protocol and contract.
At the investigator's discretion, patients who have the initial RECIST PD may continue PDR001. At any time, if assessed by the investigator that the patient is no longer benefiting from PDR001, or the patient experiences a second PD by RECIST, then the patient shall come off study medication.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Lung Cancer Metastatic, Immunotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PDR001
Arm Type
Experimental
Arm Description
PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Intervention Type
Drug
Intervention Name(s)
PDR001
Intervention Description
PDR001 300 mg (fixed dose) intraveneously every 3 weeks
Primary Outcome Measure Information:
Title
Objective response rate
Description
ORR is a proportion of patients with a best overall response defined as complete response or partial response by RECIST1.1
Time Frame
At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months]
Secondary Outcome Measure Information:
Title
Duration of response
Description
DOR is calculated as the time from the date of the first document of complete remission (CR) or partial remission (PR) to the first documented preogressive disease (PD) or death due to any cause for patients with PR or CR.
Time Frame
At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months]
Title
Progression-free survival
Description
PFS is defined as time from the first dose of investigational products (IPs) to progression or death due to any cause.
OS is defined as time from the first dose of IPs to death due to any cause.
Time Frame
At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months
Title
Overall survival
Time Frame
At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months
Title
Disease control rate
Description
DCR is calculated as the proportion of patients with best response of CR, PR and SD.
Time Frame
At Week 6 then every 6 weeks up to Week 36.and then every 12 weeks until discharge, for an average of 13.8 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects with histologically or cytologically confirmed, stage IV or recurrent NSCLC that carries a KRAS/NRAS mutation or no actionable mutation, which are identified by NGS.
Squamous cell carcinoma and non-squamous cell carcinoma will be enrolled with 1:1 ratio for efficacy analysis according to histology
Subjects who did not treated with prior anti-PD-1 antibody nor anti-PD-L1 antibodies
ECOG performance status of 0 to 2
Male or female; ≥ 18 years of age
Patients those who showed disease progression after one or two prior platinum-containing regimen
Patients who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for locally advanced disease are eligible, provided that progression has occurred ≥ 12 months from last therapy.
Subjects with at least one measurable lesion (using RECIST 1.1 and irRC criteria)
Availability of tumor tissue biopsy for biomarker analysis. Archival tissue can be used. Fine-needle aspirates will not be acceptable.
Subjects who meet the following criteria:
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥100 x 10^9/L
Serum creatinine ≥ 1.5 x upper limit of normal (ULN)
AST (SGOT) and ALT (SGPT) ≥ 3 x upper limit of normal (ULN) (If there is Liver Metastasis ≥ 5 x upper limit of normal (ULN))
Total bilirubin≥1.5 x upper limit of normal (ULN)
Life expectancy of ≥ 12 weeks on C1D1
Provision of written informed consent prior to any study specific procedures
Exclusion Criteria:
Patients who harboring EGFR mutation(s) and/or anaplastic lymphoma kinase (ALK) rearrangement will not be eligible for this trial.
Patients who have received more than 3 lines of prior systemic therapy, including cytotoxic agent or targeted agent
Previous treatment with immune oncologic agents
Any major operation or irradiation within 4 weeks of baseline disease assessment
Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms
Subjects with history of leptomeningeal metastasis
Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma or cervical cancer in situ. Any cured cancer that is considered to have no impact in PFS and OS for the current NSCLC such as thyroid cancer.
Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome (Corrected QT (QTcF) >470 ms using Fridericia's correction on the screening ECG), 2° or more AV Block and uncontrolled hypertension)
Pregnant or lactating female
Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
Active, known or suspected autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn's disease (Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll).
Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).
Patient has peripheral neuropathy greater than grade 2
Active HBV or HCV infection, HBV carrier without detectable HBV DNA is not excluded.
Known history of testing positive for Human Immunodeficiency Virus (HIV) infection
Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results.
Patients requiring chronic treatment with systemic steroid therapy or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steoids are not prohibited.
Use of any live vaccines against infectious disease within 4 weeks of initiation of study treatment.
Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 150 days after the last dose of study treatment.
Sexually active males unless they use a condom during treatment and for 150 days after stopping study treatment .
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sang-We Kim, Prof.
Phone
82-2-3010-5923
Email
swkim@amc.seoul.kr
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities
We'll reach out to this number within 24 hrs